How I Fixed My Sleep Problems for Good with CBD
You're reading How I Fixed My Sleep Problems for Good with CBD, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles.
I think
it’s safe to say that in life, we each have things we’re "working
on," right? You know, a personal habit we’re trying to break or build
upon. For me, it’s sleep. Always has been. Sleep might seem like a simple thing
that we all just naturally do, but if you’ve ever struggled to get in a few
solid hours of shut-eye (forget the full eight), then you know it can be a
pretty heavy issue to deal wi...
Source: PickTheBrain | Motivation and Self Improvement - August 5, 2019 Category: Consumer Health News Authors: Erin Falconer Tags: Erin's Things featured health and fitness self improvement cbd insomnia pickthebrain sleep Source Type: blogs
Reduce HIGH TRIGLYCERIDES naturally and safely . . . without scam products
High triglyceride levels are as common as muffin tops and man breasts. You will find a triglyceride level among the four values on any standard cholesterol panel. High triglycerides are either ignored by most doctors or reflexively “treated” with drugs, such as fibrates (Lopid, fenofibrate), prescription fish oil (Lovaza, Vascepa) and, of course, statins. But buried in this single triglyceride value is tremendous insight into diet, metabolic efficiencies, and cardiovascular risk, with control using natural, non-medication means easy to accomplish with absolute NO need for overpriced Big Pharma scam products.
Why are ...
Source: Wheat Belly Blog - December 28, 2018 Category: Cardiology Authors: Dr. Davis Tags: News & Updates grain-free triglycerides undoctored Weight Loss wheat belly Source Type: blogs
Did Big Pharma BUY Big Media?
Healthcare is at the top of the list of societal problems in the U.S.
Healthcare interactions are unsatisfying to most people, costs are out of control and cost every American nearly $10,000 per person per year while bleeding 17.5% of GDP, more than any other nation on earth for a system that ranks low or last in quality compared to other developed countries. For a problem as big as healthcare, big enough to cripple the entire economy in addition to bankrupting more and more Americans, you would think that media reporting would be filled with debate, criticisms, and in-depth coverage about the problems in healthcare.
But...
Source: Wheat Belly Blog - May 2, 2017 Category: Cardiology Authors: Dr. Davis Tags: Undoctored abc bias big pharma cbs cnn drug industry fox gluten grains health healthcare illness media nbc pharmaceutical tv wheat Source Type: blogs
Do you really need that prescription drug?
An excerpt from my new book Undoctored.
This is a story about the games that the pharmaceutical industry plays.
In this case, they are playing a shell game that costs you thousands of dollars.
Take an agent already in the public domain and classified as a nutritional supplement, perform a clinical trial to treat some condition, and then declare that this new agent is a drug. This is how prescription fish oil, Lovaza (called Omacor in Europe), got its start, when the drug company Reliant spotted the opportunity. It’s been known for decades that supplements of omega-3 fatty acids from fish oil reduce the level of triglycer...
Source: Wheat Belly Blog - May 1, 2017 Category: Cardiology Authors: Dr. Davis Tags: Omega-3 Undoctored Source Type: blogs
Understand the Wheat Belly transition
Patty shared the Wheat Belly experiences of her husband and herself recently, an example of how metabolic measures evolve over time:
“My husband and I started Wheat Belly in early January. Jeff has lost 60 pounds and I have lost 33. We both have more energy and sleep better. Even more exciting, these are Jeff’s health stats from November:
Triglyceride 687 to 164
Total Cholesterol 229 to (108 with statins); went off statins, now 178
HDL Cholesterol holding at 36
LDL (calculated) 41 to 109
A1C 11.7 to 6.4 – off two out of 3 diabetes meds
Blood Pressure 130/82 to 130/70
“My arthritic knee is no long...
Source: Wheat Belly Blog - July 12, 2016 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Success Stories diabetes gluten grains HbA1c HDL LDL triglycerides Weight Loss whaet Source Type: blogs
Stephen’s return from the medical quagmire
Stephen shared his 60-day Wheat Belly experience:
“Started Wheat Belly 60 days ago after a major health crisis. I found out I had type 2 diabetes 2 and very bad cholesterol. My numbers 60 days ago were: cholesterol 189, triglycerides 475, LDL could not be measured as it was so bad, HDL was 32. Two weeks ago: 20 pound weight loss, wearing a 15.5-inch neck size shirt compared to an 18. Triglycerides 79, LDL 25, HDL 40, cholesterol 81.
“I was first told on January 24, 2016 that my glucose level was 157. Forty five days later, my average glucose was 107 when measured by my diabetes counselor by downloading the data...
Source: Wheat Belly Blog - April 7, 2016 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Success Stories cholesterol diabetes gluten grains HDL statins triglycerides Weight Loss Source Type: blogs
How NOT to have HIGH TRIGLYCERIDES
High triglyceride levels are common, as common as muffin tops and man breasts. You will find a triglyceride level among the four values on any standard cholesterol panel. High triglycerides are either ignored by most doctors or reflexively “treated” with drugs, such as fibrates (Lopid, fenofibrate) or prescription fish oil (Lovaza). But buried in this single value is tremendous insight into diet, metabolic efficiencies, and cardiovascular risk, with control using natural, non-medication means very easy to accomplish.
Why are triglycerides important? Triglyceride levels of 60 mg/dl or higher will:
Block insu...
Source: Wheat Belly Blog - January 24, 2015 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle carbohydrates cholesterol fats fiber prebiotic resistant starch starches triglycerides Source Type: blogs
Did Pawn Star Rick Harrison Ask His Daddy About the Value of Vascepa Omega-3 Fish Oil?
Cable-TV star Rick Harrison (host of the show Pawn Stars) is now officially a celebrity spokesperson for Amarin's Omega-3 Vascepa brand Rx drug. A few minutes ago, Harrison made the official announcement via his @GoldSilverPawn Twitter account, which has over 155,000 followers: "Excited to share my story of lowering my very high #triglycerides through the new Lower My Trigs campaign: http://bit.ly/1uXxUSP #spon"“If I hadn't checked with my doctor, I would have made the mistake many make, thinking dietary supplement omega-3s are actually over-the-counter drugs,” Harrison says in a video on the site Lo...
Source: Pharma Marketing Blog - June 25, 2014 Category: Pharma Commentators Tags: Celebrity Endorsement Cholesterol Lovaza Pawn Stars Vascepa Source Type: blogs
FDA Approves New Omega-3 Supplement
The FDA has approved a new omega-3 supplement for the treatment of adults with severe hypertriglyceridemia, defined as triglyceride levels 500 mg/dL or higher. The drug, which will be marketed under the brand name of Epanova, is manufactured by AstraZeneca, which acquired the drug when it purchased Omthera Pharmaceuticals in 2013. … Click here to read the full post on Forbes. (Source: CardioBrief)
Source: CardioBrief - May 6, 2014 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes Amarin Epanova Fish oil Lovaza omega-3 triglycerides Vascepa Source Type: blogs
Studies Provide Little Support For Guidelines On Dietary Fats And Supplements
The precise cardiovascular effect of dietary fats and supplements has been the subject of heated controversy. Although there is no strong supporting evidence from clinical trials, current guidelines tend to discourage or minimize the role of saturated fats and trans fats and to encourage the intake of omega-3 polyunsaturated fatty acids. Two new studies published today help clarify some of the issues. Both studies demonstrate the shaky underpinnings of the guidelines but are unlikely to provide firm support for a new perspective on these issues. … Click here to read the full post on Forbes. (Source: CardioBrief)
Source: CardioBrief - March 17, 2014 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes diet fats fatty acids fish oils nutrition omega-3 fatty acids Saturated fat supplements Source Type: blogs
Will FDA Widen Use For The Vasecpa Fish Oil Pill, After All?
In a surprising development that has revived intense speculation over the fate of Amarin, the FDA has delayed any decision about whether to widen an indication for the Vascepa prescription fish oil pill. The move was expected last Friday and the delay has now triggered intrigue over what appears to be a complex minuet between the agency and the ‘little drugmaker that could.’
In explaining the rationale for the FDA delay, Amarin released a brief statement saying the agency has not disclosed when a decision may be made on the Vascepa indication. But Amarin attributed the delay to its recent appeal of an FDA decision to r...
Source: Pharmalot - December 23, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
As FDA Decision Nears, Amarin CEO Retires And Investors Petition
Just days before the FDA is expected to decide whether to approve the controversial Vascepa fish oil pill that is sold by Amarin, the little drugmaker has announced that its chairman and chief executive, Joseph Zakrzewski, is retiring at the end of the month. John Thero, who has been Amarin president since 2009, was promoted to replace him (here is the statement).
The move caps a disappointing year for Amarin, which has been one of the more interesting biotech stock stories of the past year. Two months ago, an FDA advisory committee voted against recommending broader use of Vascepa until an outcomes study is completed in 2...
Source: Pharmalot - December 16, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Amarin Appeals FDA Rescission Of Special Protocol Agreement
File this under ‘best of luck.’ One week after the FDA rescinded a special protocol agreement that Amarin was counting on to significantly widen usage for its Vascepa prescription fish oil pill, the drugmaker has filed an appeal (see page 18). Whether the agency will change its collective mind is unclear, but a reversal is likely to be a long shot, at best.
The effort is the latest twist in what has been one of the more closely watched biopharma stock stories on Wall Street this year. Investors were captivated by the possibility that the drugmaker might have been able to market a potential blockbuster amid a heated deb...
Source: Pharmalot - November 8, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
FDA Rescinds Special Protocol Agreement For Amarin Fish Oil Pill
In yet another blow to Amarin, the FDA has rescinded a special protocol agreement that the drugmaker was counting on to widen usage for its Vascepa prescription fish oil pill, according to a filing with the US Securities and Exchange Commission. The disclosure comes two weeks after an FDA advisory committee voted 9-to-2 against recommending broader use until an outcomes study is completed in 2016.
The decision by the FDA may finally put to rest what has been one of the more interesting stock stories in the biopharma universe this past year. Investors were captivated by the possibility that the company might market a potent...
Source: Pharmalot - October 30, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Whither Amarin? FDA Panel Rejects Wider Use For Its Fish Oil Pill
In a huge setback for Amarin, an FDA advisory committee voted 9-to-2 against recommending broader use of the Vascepa prescription fish oil pill. Specifically, the panel believes the agency should wait for the results of an ongoing outcomes study to determine whether its pill can demonstrate definitive evidence that there are cardiovascular benefits. That study is expected to be completed in 2016.
Although the panelists agreed that Vascepa significantly lowers triglyceride levels, they expressed uncertainty about whether that can translate into fewer heart attacks. "I am wary of approving a drug that has a potential mark...
Source: Pharmalot - October 16, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
